[go: up one dir, main page]

WO2008062309A3 - Molécules anti-coronavirus et leur utilisation dans des compositions et procédés pour traiter et/ou prévenir une infection provoquée par un coronavirus - Google Patents

Molécules anti-coronavirus et leur utilisation dans des compositions et procédés pour traiter et/ou prévenir une infection provoquée par un coronavirus Download PDF

Info

Publication number
WO2008062309A3
WO2008062309A3 PCT/IB2007/004174 IB2007004174W WO2008062309A3 WO 2008062309 A3 WO2008062309 A3 WO 2008062309A3 IB 2007004174 W IB2007004174 W IB 2007004174W WO 2008062309 A3 WO2008062309 A3 WO 2008062309A3
Authority
WO
WIPO (PCT)
Prior art keywords
coronavirus
molecules
compositions
treating
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/004174
Other languages
English (en)
Other versions
WO2008062309A2 (fr
Inventor
Beatrice Therese Marie Nal-Rogier
Ralf Marius Altmeyer
Francois Kien
Jean Millet
Kim Tat Teoh
Yu Lam Siu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Hong Kong HKU
Original Assignee
University of Hong Kong HKU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Hong Kong HKU filed Critical University of Hong Kong HKU
Publication of WO2008062309A2 publication Critical patent/WO2008062309A2/fr
Publication of WO2008062309A3 publication Critical patent/WO2008062309A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)

Abstract

La présente invention porte sur le domaine des coronavirus et, plus particulièrement, sur des molécules anti-coronavirus et sur leur utilisation dans des compositions, et sur des procédés pour traiter et/ou prévenir une infection provoquée par un coronavirus, tel que celui responsable du syndrome respiratoire aigu grave (SARS). La présente invention porte également sur un procédé pour cribler de nouvelles molécules anti-coronavirus.
PCT/IB2007/004174 2006-11-20 2007-11-20 Molécules anti-coronavirus et leur utilisation dans des compositions et procédés pour traiter et/ou prévenir une infection provoquée par un coronavirus Ceased WO2008062309A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,569,080 2006-11-20
CA002569080A CA2569080A1 (fr) 2006-11-20 2006-11-20 Molecules anti-coronavirus et leur utilisation dans les compositions, et methodes de traitement et/ou prevention de l'infection causee par un coronavirus

Publications (2)

Publication Number Publication Date
WO2008062309A2 WO2008062309A2 (fr) 2008-05-29
WO2008062309A3 true WO2008062309A3 (fr) 2008-12-04

Family

ID=39420417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004174 Ceased WO2008062309A2 (fr) 2006-11-20 2007-11-20 Molécules anti-coronavirus et leur utilisation dans des compositions et procédés pour traiter et/ou prévenir une infection provoquée par un coronavirus

Country Status (2)

Country Link
CA (1) CA2569080A1 (fr)
WO (1) WO2008062309A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111675752B (zh) * 2020-03-16 2023-07-07 成都奥达生物科技有限公司 一种冠状病毒膜融合抑制剂及其药物用途
WO2022024108A1 (fr) * 2020-07-28 2022-02-03 Rapo Yerape B.H. Ltd. Peptide d'ezrine (hep-1) destiné à être utilisé dans le traitement d'une maladie à coronavirus
US20230057094A1 (en) 2020-08-29 2023-02-23 Rosa Maria Portillo Rosado Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047150A2 (fr) * 1998-03-18 1999-09-23 Institut Curie Composition pharmaceutique contenant de l'ezrine mutee sur la tyrosine 353

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047150A2 (fr) * 1998-03-18 1999-09-23 Institut Curie Composition pharmaceutique contenant de l'ezrine mutee sur la tyrosine 353

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HO ET AL: "Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction", ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 69, no. 2, 1 February 2006 (2006-02-01), pages 70 - 76, XP005269148, ISSN: 0166-3542 *
HO ET AL: "Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction", ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 74, no. 2, 23 March 2007 (2007-03-23), pages 92 - 101, XP005933984, ISSN: 0166-3542 *
HO T-Y ET AL: "Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 313, no. 4, 23 January 2004 (2004-01-23), pages 938 - 947, XP004482920, ISSN: 0006-291X *
STADLER K ET AL: "SARS - BEGINNING TO UNDERSTAND A NEW VIRUS", NATURE REVIEWS. MICROBIOLOGY, NATURE PUBLISHING GROUP, GB, vol. 1, no. 3, 1 December 2003 (2003-12-01), pages 209 - 218, XP009059463, ISSN: 1740-1526 *
YI L ET AL: "Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 78, no. 20, 1 October 2004 (2004-10-01), pages 11334 - 11339, XP002993121, ISSN: 0022-538X *

Also Published As

Publication number Publication date
CA2569080A1 (fr) 2008-05-20
WO2008062309A2 (fr) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2007092622A3 (fr) Compositions et méthodes pour le traitement d'os
IL194865A0 (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2010053573A3 (fr) Criblage d'inhibiteurs de filovirus et leurs utilisations
PL2302055T3 (pl) Sposoby i kompozycje z wykorzystaniem miRNA oraz cząsteczek inhibitorowych miRNA
AU2007208223A8 (en) Methods and compositions for treating schizophrenia
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
WO2009067245A3 (fr) Compositions et procédés de réparation de tissu
WO2008128072A3 (fr) Inhibiteurs de la kinase axl
WO2007127841A3 (fr) Compositions et leurs méthodes d'élaboration
WO2008073463A3 (fr) Méthodes et compositions pour le traitement et le contrôle d'un traitement de troubles associés à il-13
WO2007095116A3 (fr) Compositions de verre pour verres de protection et procedes de fabrication et d'utilisation de ces compositions
WO2009077471A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2009120810A3 (fr) Troubles neurodégénératifs
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2007127204A3 (fr) Méthodes et compositions concernant une immunostimulation
WO2007140205A3 (fr) Procédés de traitement de fibrose
WO2009129497A3 (fr) Methodes et compositions de traitement de la degenerescence maculaire liee a l’age et d’identification de composes appropries
WO2009009034A3 (fr) Procédées et compositions utiles dans le traitement de la mucosite
WO2008062309A3 (fr) Molécules anti-coronavirus et leur utilisation dans des compositions et procédés pour traiter et/ou prévenir une infection provoquée par un coronavirus
WO2008148747A8 (fr) Modulateurs du domaine pdz
ZA200706662B (en) Haloaryl substituted Aminopurines, compositions thereof, and methods of treatment therewith
WO2007117419A3 (fr) Procédés et compositions associés à des inhibiteurs d'une enzyme de clivage post-prolyle
WO2010030641A3 (fr) Marqueurs du cancer du pancréas
WO2009158387A3 (fr) Compositions, formulations, et procédés permettant de prévenir et/ou de traiter des effets physiques de la consommation d'alcool
WO2010068717A3 (fr) Désactivateurs pyrazolinone de radicaux libres

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859238

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07859238

Country of ref document: EP

Kind code of ref document: A2